What is Quest Diagnostics Inc's earnings per share (EPS)?

Quest Diagnostics Inc (DGX) reported diluted earnings per share of $8.75 for fiscal year 2025. This represents a 13.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Quest Diagnostics Inc Financials

DGX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Quest Diagnostics Inc (DGX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 51/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Quest Diagnostics Inc has an operating margin of 14.1%, meaning the company retains $14 of operating profit per $100 of revenue. This results in a moderate score of 54/100, indicating healthy but not exceptional operating efficiency. This is up from 13.6% the prior year.

Growth

Quest Diagnostics Inc's revenue grew 11.8% year-over-year to $11.0B, a solid pace of expansion. This earns a growth score of 53/100.

Leverage

Quest Diagnostics Inc carries a low D/E ratio of 0.72, meaning only $0.72 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 87/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Quest Diagnostics Inc's current ratio of 1.04 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 16/100, which could limit financial flexibility.

Cash Flow

Quest Diagnostics Inc has a free cash flow margin of 12.3%, earning a moderate score of 56/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Quest Diagnostics Inc's ROE of 13.8% shows moderate profitability relative to equity, earning a score of 42/100. This is up from 12.8% the prior year.

Altman Z-Score Safe

3.29

Quest Diagnostics Inc scores 3.29, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Strong

8/9

Quest Diagnostics Inc passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.90x

For every $1 of reported earnings, Quest Diagnostics Inc generates $1.90 in operating cash flow ($1.9B OCF vs $992.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.6x

Quest Diagnostics Inc earns $5.6 in operating income for every $1 of interest expense ($1.6B vs $277.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$11.0B

YoY+11.8%

5Y CAGR+3.2%

10Y CAGR+3.9%

Quest Diagnostics Inc generated $11.0B in revenue in fiscal year 2025. This represents an increase of 11.8% from the prior year.

EBITDA

$2.1B

YoY+15.6%

5Y CAGR-1.8%

10Y CAGR+2.2%

Quest Diagnostics Inc's EBITDA was $2.1B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.6% from the prior year.

Net Income

$992.0M

YoY+13.9%

5Y CAGR-7.1%

10Y CAGR+3.4%

Quest Diagnostics Inc reported $992.0M in net income in fiscal year 2025. This represents an increase of 13.9% from the prior year.

EPS (Diluted)

$8.75

YoY+13.8%

5Y CAGR-3.5%

10Y CAGR+6.0%

Quest Diagnostics Inc earned $8.75 per diluted share (EPS) in fiscal year 2025. This represents an increase of 13.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.4B

YoY+49.5%

5Y CAGR-3.1%

10Y CAGR+9.3%

Quest Diagnostics Inc generated $1.4B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 49.5% from the prior year.

Cash & Debt

$420.0M

YoY-23.5%

5Y CAGR-18.4%

10Y CAGR+12.2%

Quest Diagnostics Inc held $420.0M in cash against $5.2B in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

110M

YoY-1.0%

5Y CAGR-3.8%

10Y CAGR-2.6%

Quest Diagnostics Inc had 110M shares outstanding in fiscal year 2025. This represents a decrease of 1.0% from the prior year.

Margins & Returns

Gross Margin

33.2%

YoY+0.4pp

5Y CAGR-5.3pp

10Y CAGR-4.6pp

Quest Diagnostics Inc's gross margin was 33.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the prior year.

Operating Margin

14.1%

YoY+0.5pp

5Y CAGR-6.8pp

10Y CAGR-4.6pp

Quest Diagnostics Inc's operating margin was 14.1% in fiscal year 2025, reflecting core business profitability. This is up 0.5 percentage points from the prior year.

Net Margin

9.0%

YoY+0.2pp

5Y CAGR-6.2pp

10Y CAGR-0.5pp

Quest Diagnostics Inc's net profit margin was 9.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 0.2 percentage points from the prior year.

Return on Equity

13.8%

YoY+1.0pp

5Y CAGR-7.3pp

10Y CAGR-1.3pp

Quest Diagnostics Inc's ROE was 13.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 1.0 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

$450.0M

YoY+198.0%

5Y CAGR+6.7%

10Y CAGR+7.2%

Quest Diagnostics Inc spent $450.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 198.0% from the prior year.

Capital Expenditures

$527.0M

YoY+24.0%

5Y CAGR+4.7%

10Y CAGR+7.2%

Quest Diagnostics Inc invested $527.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 24.0% from the prior year.

DGX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$11.0B+11.8%	$9.9B+6.7%	$9.3B-6.4%	$9.9B-8.4%	$10.8B+14.3%	$9.4B
Cost of Revenue	$7.4B+11.2%	$6.6B+6.9%	$6.2B-3.9%	$6.5B-2.0%	$6.6B+13.4%	$5.8B
Gross Profit	$3.7B+13.0%	$3.2B+6.3%	$3.1B-11.1%	$3.4B-18.4%	$4.2B+15.9%	$3.6B
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$2.0B+11.1%	$1.8B+7.8%	$1.6B-12.4%	$1.9B+8.5%	$1.7B+11.4%	$1.6B
Operating Income	$1.6B+15.6%	$1.3B+6.7%	$1.3B-11.6%	$1.4B-40.0%	$2.4B+20.8%	$2.0B
Interest Expense	$277.0M+22.6%	$226.0M+38.7%	$163.0M+10.1%	$148.0M-2.6%	$152.0M-8.4%	$166.0M
Income Tax	$314.0M+15.0%	$273.0M+10.1%	$248.0M-6.1%	$264.0M-55.8%	$597.0M+29.8%	$460.0M
Net Income	$992.0M+13.9%	$871.0M+2.0%	$854.0M-9.7%	$946.0M-52.6%	$2.0B+39.4%	$1.4B
EPS (Diluted)	$8.75+13.8%	$7.69+2.7%	$7.49-6.0%	$7.97-48.7%	$15.55+48.5%	$10.47

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$2.8B-0.4%	$2.8B+2.0%	$2.8B+4.1%	$2.7B+1.2%	$2.6B+5.3%	$2.5B+3.8%	$2.4B+1.3%	$2.4B
Cost of Revenue	$1.9B+1.6%	$1.9B+2.7%	$1.8B+1.6%	$1.8B+1.5%	$1.8B+5.1%	$1.7B+5.3%	$1.6B-0.1%	$1.6B
Gross Profit	$910.0M-4.1%	$949.0M+0.6%	$943.0M+9.3%	$863.0M+0.6%	$858.0M+5.8%	$811.0M+0.9%	$804.0M+4.3%	$771.0M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$504.0M+0.6%	$501.0M+3.1%	$486.0M+2.1%	$476.0M+2.1%	$466.0M+4.0%	$448.0M+7.7%	$416.0M-5.5%	$440.0M
Operating Income	$386.0M0.0%	$386.0M-11.9%	$438.0M+26.6%	$346.0M-4.2%	$361.0M+9.4%	$330.0M-7.0%	$355.0M+18.3%	$300.0M
Interest Expense	$67.0M-2.9%	$69.0M0.0%	$69.0M-4.2%	$72.0M0.0%	$72.0M+24.1%	$58.0M+23.4%	$47.0M-4.1%	$49.0M
Income Tax	$81.0M+5.2%	$77.0M-20.6%	$97.0M+64.4%	$59.0M-13.2%	$68.0M+4.6%	$65.0M-12.2%	$74.0M+12.1%	$66.0M
Net Income	$245.0M0.0%	$245.0M-13.1%	$282.0M+28.2%	$220.0M-0.9%	$222.0M-1.8%	$226.0M-1.3%	$229.0M+18.0%	$194.0M
EPS (Diluted)	N/A	$2.16-12.6%	$2.47+27.3%	$1.94	N/A	$1.99-2.0%	$2.03+18.0%	$1.72

DGX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$16.2B+0.4%	$16.2B+15.2%	$14.0B+9.2%	$12.8B-5.7%	$13.6B-3.0%	$14.0B
Current Assets	$2.4B-0.6%	$2.4B+0.8%	$2.4B+25.0%	$1.9B-30.8%	$2.7B-10.4%	$3.1B
Cash & Equivalents	$420.0M-23.5%	$549.0M-20.0%	$686.0M+117.8%	$315.0M-63.9%	$872.0M-24.7%	$1.2B
Inventory	$189.0M+0.5%	$188.0M-1.1%	$190.0M-1.0%	$192.0M-7.7%	$208.0M-6.7%	$223.0M
Accounts Receivable	$1.4B+8.0%	$1.3B+7.8%	$1.2B+1.3%	$1.2B-16.9%	$1.4B-5.4%	$1.5B
Goodwill	$8.9B+1.0%	$8.9B+14.5%	$7.7B+7.1%	$7.2B+1.8%	$7.1B+3.2%	$6.9B
Total Liabilities	$9.1B-3.4%	$9.4B+21.5%	$7.7B+11.1%	$6.9B-3.1%	$7.2B-1.4%	$7.3B
Current Liabilities	$2.3B+5.0%	$2.2B+19.5%	$1.8B+17.0%	$1.6B-11.5%	$1.8B-1.3%	$1.8B
Long-Term Debt	$5.2B-8.0%	$5.6B+27.3%	$4.4B+10.9%	$4.0B-0.8%	$4.0B-0.1%	$4.0B
Total Equity	$7.2B+5.8%	$6.8B+7.5%	$6.3B+7.0%	$5.9B-8.6%	$6.4B-4.7%	$6.8B
Retained Earnings	$10.0B+6.8%	$9.4B+6.1%	$8.8B+6.5%	$8.3B+8.4%	$7.6B-17.8%	$9.3B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$16.2B+0.2%	$16.2B+1.4%	$16.0B+1.1%	$15.8B-2.2%	$16.2B+0.4%	$16.1B+15.9%	$13.9B-0.5%	$14.0B
Current Assets	$2.4B-1.2%	$2.4B+9.5%	$2.2B+5.9%	$2.1B-13.3%	$2.4B-8.8%	$2.6B+30.0%	$2.0B-9.5%	$2.2B
Cash & Equivalents	$420.0M-2.8%	$432.0M+35.4%	$319.0M+69.7%	$188.0M-65.8%	$549.0M-28.1%	$764.0M+181.9%	$271.0M-42.8%	$474.0M
Inventory	$189.0M+1.6%	$186.0M-0.5%	$187.0M-1.1%	$189.0M+0.5%	$188.0M+2.2%	$184.0M+1.1%	$182.0M+0.6%	$181.0M
Accounts Receivable	$1.4B-3.3%	$1.5B+2.6%	$1.4B+1.1%	$1.4B+7.7%	$1.3B-5.2%	$1.4B+4.3%	$1.3B-0.2%	$1.3B
Goodwill	$8.9B+0.5%	$8.9B+0.2%	$8.9B+0.4%	$8.8B-0.1%	$8.9B+2.9%	$8.6B+9.1%	$7.9B+0.7%	$7.8B
Total Liabilities	$9.1B+1.3%	$8.9B+2.3%	$8.7B-1.4%	$8.9B-5.4%	$9.4B+1.0%	$9.3B+27.8%	$7.3B-3.4%	$7.5B
Current Liabilities	$2.3B+6.7%	$2.1B+5.4%	$2.0B+40.5%	$1.4B-33.6%	$2.2B+3.7%	$2.1B+4.0%	$2.0B-12.4%	$2.3B
Long-Term Debt	$5.2B-0.1%	$5.2B0.0%	$5.2B-11.8%	$5.9B+4.3%	$5.6B-0.6%	$5.6B+48.0%	$3.8B+0.3%	$3.8B
Total Equity	$7.2B-1.2%	$7.3B+0.4%	$7.2B+4.3%	$6.9B+2.2%	$6.8B-0.5%	$6.8B+2.9%	$6.6B+2.9%	$6.4B
Retained Earnings	$10.0B+1.6%	$9.8B+1.6%	$9.7B+2.0%	$9.5B+1.4%	$9.4B+1.5%	$9.2B+1.6%	$9.1B+1.6%	$8.9B

DGX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.9B+41.4%	$1.3B+4.9%	$1.3B-26.0%	$1.7B-23.1%	$2.2B+11.4%	$2.0B
Capital Expenditures	$527.0M+24.0%	$425.0M+4.2%	$408.0M+1.0%	$404.0M+0.2%	$403.0M-3.6%	$418.0M
Free Cash Flow	$1.4B+49.5%	$909.0M+5.2%	$864.0M-34.2%	$1.3B-28.2%	$1.8B+15.3%	$1.6B
Investing Cash Flow	-$631.0M+75.2%	-$2.5B-140.2%	-$1.1B-95.4%	-$543.0M-2685.7%	$21.0M+102.7%	-$772.0M
Financing Cash Flow	-$1.4B-228.0%	$1.1B+577.5%	$160.0M+109.2%	-$1.7B+31.8%	-$2.5B-100.5%	-$1.3B
Dividends Paid	$353.0M+6.6%	$331.0M+5.4%	$314.0M+3.0%	$305.0M-1.3%	$309.0M+4.0%	$297.0M
Share Buybacks	$450.0M+198.0%	$151.0M-45.1%	$275.0M-80.5%	$1.4B-36.0%	$2.2B+576.6%	$325.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$465.0M-17.4%	$563.0M+3.5%	$544.0M+73.2%	$314.0M-32.3%	$464.0M+30.3%	$356.0M-1.1%	$360.0M+133.8%	$154.0M
Capital Expenditures	$158.0M+9.7%	$144.0M+33.3%	$108.0M-7.7%	$117.0M-4.9%	$123.0M+16.0%	$106.0M+15.2%	$92.0M-11.5%	$104.0M
Free Cash Flow	$307.0M-26.7%	$419.0M-3.9%	$436.0M+121.3%	$197.0M-42.2%	$341.0M+36.4%	$250.0M-6.7%	$268.0M+436.0%	$50.0M
Investing Cash Flow	-$191.0M+5.0%	-$201.0M-62.1%	-$124.0M-7.8%	-$115.0M+77.1%	-$502.0M+69.3%	-$1.6B-716.5%	-$200.0M+6.1%	-$213.0M
Financing Cash Flow	-$287.0M-16.2%	-$247.0M+15.7%	-$293.0M+47.8%	-$561.0M-230.0%	-$170.0M-109.6%	$1.8B+587.6%	-$363.0M-137.3%	-$153.0M
Dividends Paid	$90.0M+1.1%	$89.0M-1.1%	$90.0M+7.1%	$84.0M0.0%	$84.0M0.0%	$84.0M0.0%	$84.0M+6.3%	$79.0M
Share Buybacks	$300.0M	N/A	N/A	N/A	$151.0M	N/A	N/A	N/A

DGX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	33.2%+0.4pp	32.9%-0.1pp	33.0%-1.7pp	34.7%-4.3pp	39.0%+0.5pp	38.5%
Operating Margin	14.1%+0.5pp	13.6%0.0pp	13.6%-0.8pp	14.4%-7.6pp	22.1%+1.2pp	20.9%
Net Margin	9.0%+0.2pp	8.8%-0.4pp	9.2%-0.3pp	9.6%-8.9pp	18.5%+3.3pp	15.2%
Return on Equity	13.8%+1.0pp	12.8%-0.7pp	13.5%-2.5pp	16.1%-14.9pp	31.0%+9.8pp	21.2%
Return on Assets	6.1%+0.7pp	5.4%-0.7pp	6.1%-1.3pp	7.4%-7.3pp	14.7%+4.5pp	10.2%
Current Ratio	1.04-0.1	1.10-0.2	1.31+0.1	1.22-0.3	1.56-0.2	1.72
Debt-to-Equity	0.72-0.1	0.83+0.1	0.70+0.0	0.68+0.1	0.62+0.0	0.59
FCF Margin	12.3%+3.1pp	9.2%-0.1pp	9.3%-4.0pp	13.3%-3.7pp	17.0%+0.1pp	16.8%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	32.4%-1.3pp	33.7%-0.5pp	34.2%+1.6pp	32.5%-0.2pp	32.7%+0.1pp	32.6%-0.9pp	33.5%+0.9pp	32.6%
Operating Margin	13.8%+0.1pp	13.7%-2.1pp	15.9%+2.8pp	13.1%-0.7pp	13.8%+0.5pp	13.3%-1.6pp	14.8%+2.1pp	12.7%
Net Margin	8.7%+0.0pp	8.7%-1.5pp	10.2%+1.9pp	8.3%-0.2pp	8.5%-0.6pp	9.1%-0.5pp	9.6%+1.3pp	8.2%
Return on Equity	3.4%+0.0pp	3.4%-0.5pp	3.9%+0.7pp	3.2%-0.1pp	3.3%-0.0pp	3.3%-0.1pp	3.5%+0.4pp	3.0%
Return on Assets	1.5%0.0pp	1.5%-0.3pp	1.8%+0.4pp	1.4%+0.0pp	1.4%-0.0pp	1.4%-0.3pp	1.7%+0.3pp	1.4%
Current Ratio	1.04-0.1	1.13+0.0	1.09-0.4	1.44+0.3	1.10-0.2	1.25+0.3	1.00+0.0	0.97
Debt-to-Equity	0.720.0	0.710.0	0.72-0.1	0.85+0.0	0.830.0	0.83+0.3	0.58-0.0	0.59
FCF Margin	10.9%-3.9pp	14.9%-0.9pp	15.8%+8.4pp	7.4%-5.6pp	13.0%+3.0pp	10.1%-1.1pp	11.2%+9.1pp	2.1%

Similar Companies

Labcorp Holdings Inc LH

$22.0B

$29.2B

$28.3B

$14.5B

$25.5B

Frequently Asked Questions

What is Quest Diagnostics Inc's annual revenue?

Quest Diagnostics Inc (DGX) reported $11.0B in total revenue for fiscal year 2025. This represents a 11.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Quest Diagnostics Inc's revenue growing?

Quest Diagnostics Inc (DGX) revenue grew by 11.8% year-over-year, from $9.9B to $11.0B in fiscal year 2025.

Is Quest Diagnostics Inc profitable?

Yes, Quest Diagnostics Inc (DGX) reported a net income of $992.0M in fiscal year 2025, with a net profit margin of 9.0%.

What is Quest Diagnostics Inc's EBITDA?

Quest Diagnostics Inc (DGX) had EBITDA of $2.1B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Quest Diagnostics Inc have?

As of fiscal year 2025, Quest Diagnostics Inc (DGX) had $420.0M in cash and equivalents against $5.2B in long-term debt.

What is Quest Diagnostics Inc's gross margin?

Quest Diagnostics Inc (DGX) had a gross margin of 33.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Quest Diagnostics Inc's operating margin?

Quest Diagnostics Inc (DGX) had an operating margin of 14.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Quest Diagnostics Inc's net profit margin?

Quest Diagnostics Inc (DGX) had a net profit margin of 9.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Quest Diagnostics Inc's return on equity (ROE)?

Quest Diagnostics Inc (DGX) has a return on equity of 13.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Quest Diagnostics Inc's free cash flow?

Quest Diagnostics Inc (DGX) generated $1.4B in free cash flow during fiscal year 2025. This represents a 49.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Quest Diagnostics Inc's operating cash flow?

Quest Diagnostics Inc (DGX) generated $1.9B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Quest Diagnostics Inc's total assets?

Quest Diagnostics Inc (DGX) had $16.2B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Quest Diagnostics Inc's capital expenditures?

Quest Diagnostics Inc (DGX) invested $527.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Quest Diagnostics Inc buy back shares?

Yes, Quest Diagnostics Inc (DGX) spent $450.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Quest Diagnostics Inc have outstanding?

Quest Diagnostics Inc (DGX) had 110M shares outstanding as of fiscal year 2025.

What is Quest Diagnostics Inc's current ratio?

Quest Diagnostics Inc (DGX) had a current ratio of 1.04 as of fiscal year 2025, which is considered adequate.

What is Quest Diagnostics Inc's debt-to-equity ratio?

Quest Diagnostics Inc (DGX) had a debt-to-equity ratio of 0.72 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Quest Diagnostics Inc's return on assets (ROA)?

Quest Diagnostics Inc (DGX) had a return on assets of 6.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Quest Diagnostics Inc's Altman Z-Score?

Quest Diagnostics Inc (DGX) has an Altman Z-Score of 3.29, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Quest Diagnostics Inc's Piotroski F-Score?

Quest Diagnostics Inc (DGX) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Quest Diagnostics Inc's earnings high quality?

Quest Diagnostics Inc (DGX) has an earnings quality ratio of 1.90x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Quest Diagnostics Inc cover its interest payments?

Quest Diagnostics Inc (DGX) has an interest coverage ratio of 5.6x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Quest Diagnostics Inc?

Quest Diagnostics Inc (DGX) scores 51 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.